Shots:  

• The company has reported the first patient dosing in the P-I CALOSOMA study assessing the safety- tolerability- PK/PD of GLPG3970 single & multiple ascending doses in up to 52 adult healthy male subjects. The therapy will now be evaluated in 25 patients with moderate to severe psoriasis for 6wks.
• Galapagos is also evaluating the potential of GLPG3970 in the P-II SEA TURTLE study for patients with mod. to sev. active UC and in P-II LADYBUG study for patients with severely active RA who had an inadequate response to MTX
• Galapagos plans to unveil the novel Toledo target class and will share GLPG3970 P-I data at its inaugural Toledo Roundtable to be held virtually on Oct 27- 2020

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: European Technology